News

Neurotech Pharmaceuticals enhances its leadership by appointing Peter J. McDonnell, MD, a leading ophthalmology expert, to its Board of Directors.

MCO-010 receives Orphan and RMAT designations, highlighting its potential as a groundbreaking therapy for various retinal dystrophies.

Virtual reality and artificial intelligence are reshaping medical education.

Alfredo Sadun, MD, PhD, details an unexpected outcome from a gene therapy in development for Leber hereditary optic neuropathy (LHON).

Presentation topics will include therapies for age-related macular degeneration, X-linked retinitis pigmentosa and other retinal pathologies

identifeye HEALTH unveils a retinal screening platform, enhancing accessibility and efficiency in patient care through innovative technology and AI integration.

The goal is to provide an end-to-end operating system that unifies clinical, operational, and financial workflows.

The committee will work to help the organization increase awareness and early identification of diabetes-related eye diseases and improve access to eye care treatment, policy development, research, and surveillance.

Jeremiah Tao, MD, FACS, highlights essential safety strategies in oculofacial surgery, emphasizing cost-effective techniques to prevent complications and enhance patient care.

Jeremiah Tao, MD, FACS, used his Egyptian Ophthalmological Society keynote to explore complex and costly challenges in oculofacial surgery

Recapping the Heidelberg Engineering International SPECTRALIS Symposium—and Beyond.

Researchers used adaptive optics scanning light ophthalmoscopy (AOSLO) to study retinas in mice with photoreceptor damage, specifically photoreceptor laser injury.

Clinical leaders including Susan Schneider, MD; Lejla Vajzovic, MD; and Harvey Uy, MD, will share new clinical findings

Advancements in retinal therapies and technologies are scheduled to be showcased at EURETINA 2025 from Clearside, ZEISS, and Ashvattha Therapeutics.

FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.

Surgical tools improve Schlemm canal access and enable earlier glaucoma care.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration.

As myopia becomes a worldwide epidemic, the upcoming Paris workshop on September 8, 2025, will convene global leaders to discuss strategies, research priorities, and new treatment pathways.

An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration

Ahead of the September 8 meeting in Paris, the program co-chair of the event and current president of the American Academy of Ophthalmology discusses how the workshop aims to shape consensus on guidelines, research priorities, and emerging therapies in myopia control.

A novel use of minor salivary glands offers lasting relief and visual improvement.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Where to find members of our editorial board at this year's European Society of Retina Specialists Congress

At the 2025 EURETINA Congress, keep an eye out for 11 editorial advisory board members from Modern Retina, Ophthalmology Times and Ophthalmology Times Europe.

Long-term cannabis use may reduce the risk of proliferative vitreoretinopathy after retinal detachment surgery, suggesting potential therapeutic benefits.